CN117310035A - Application of organic salt in water-soluble vitamin detection kit - Google Patents
Application of organic salt in water-soluble vitamin detection kit Download PDFInfo
- Publication number
- CN117310035A CN117310035A CN202311268846.9A CN202311268846A CN117310035A CN 117310035 A CN117310035 A CN 117310035A CN 202311268846 A CN202311268846 A CN 202311268846A CN 117310035 A CN117310035 A CN 117310035A
- Authority
- CN
- China
- Prior art keywords
- water
- vitamin
- organic salt
- formate
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940088594 vitamin Drugs 0.000 title claims abstract description 63
- 229930003231 vitamin Natural products 0.000 title claims abstract description 63
- 235000013343 vitamin Nutrition 0.000 title claims abstract description 63
- 239000011782 vitamin Substances 0.000 title claims abstract description 63
- 150000003839 salts Chemical class 0.000 title claims abstract description 36
- 238000001514 detection method Methods 0.000 title claims abstract description 26
- 150000003722 vitamin derivatives Chemical class 0.000 title claims abstract description 18
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 32
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims abstract description 20
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000007864 aqueous solution Substances 0.000 claims abstract description 19
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 17
- ZIYVHBGGAOATLY-UHFFFAOYSA-N methylmalonic acid Chemical compound OC(=O)C(C)C(O)=O ZIYVHBGGAOATLY-UHFFFAOYSA-N 0.000 claims abstract description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims abstract description 13
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims abstract description 12
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 229960002477 riboflavin Drugs 0.000 claims abstract description 12
- 239000011677 pyridoxine Substances 0.000 claims abstract description 11
- 229960003495 thiamine Drugs 0.000 claims abstract description 11
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 11
- 235000007635 levomefolic acid Nutrition 0.000 claims abstract description 10
- 239000011578 levomefolic acid Substances 0.000 claims abstract description 10
- 235000008160 pyridoxine Nutrition 0.000 claims abstract description 10
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229930003451 Vitamin B1 Natural products 0.000 claims abstract description 7
- 229930003471 Vitamin B2 Natural products 0.000 claims abstract description 7
- 239000002253 acid Substances 0.000 claims abstract description 7
- 239000000872 buffer Substances 0.000 claims abstract description 7
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract description 7
- 235000010374 vitamin B1 Nutrition 0.000 claims abstract description 7
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 7
- 235000019164 vitamin B2 Nutrition 0.000 claims abstract description 7
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 7
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims abstract description 6
- 229930003571 Vitamin B5 Natural products 0.000 claims abstract description 5
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims abstract description 5
- 229960002079 calcium pantothenate Drugs 0.000 claims abstract description 5
- 235000009492 vitamin B5 Nutrition 0.000 claims abstract description 5
- 239000011675 vitamin B5 Substances 0.000 claims abstract description 5
- 238000003908 quality control method Methods 0.000 claims description 40
- 239000000243 solution Substances 0.000 claims description 32
- 210000002966 serum Anatomy 0.000 claims description 28
- 239000007853 buffer solution Substances 0.000 claims description 27
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical group [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 claims description 19
- 239000011159 matrix material Substances 0.000 claims description 18
- 239000011550 stock solution Substances 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000012491 analyte Substances 0.000 claims description 10
- 102000004506 Blood Proteins Human genes 0.000 claims description 7
- 108010017384 Blood Proteins Proteins 0.000 claims description 7
- 159000000021 acetate salts Chemical class 0.000 claims description 7
- 238000004811 liquid chromatography Methods 0.000 claims description 7
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical group N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 6
- 239000005695 Ammonium acetate Substances 0.000 claims description 6
- 235000019257 ammonium acetate Nutrition 0.000 claims description 6
- 229940043376 ammonium acetate Drugs 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 238000007865 diluting Methods 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 230000002335 preservative effect Effects 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 238000004587 chromatography analysis Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000004885 tandem mass spectrometry Methods 0.000 claims description 3
- 239000000523 sample Substances 0.000 description 19
- 239000000047 product Substances 0.000 description 17
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 239000007789 gas Substances 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 5
- 235000019253 formic acid Nutrition 0.000 description 5
- 235000019192 riboflavin Nutrition 0.000 description 5
- 239000002151 riboflavin Substances 0.000 description 5
- 238000010257 thawing Methods 0.000 description 5
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 235000019157 thiamine Nutrition 0.000 description 4
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 4
- 239000011721 thiamine Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 238000004807 desolvation Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 229960003966 nicotinamide Drugs 0.000 description 3
- 235000005152 nicotinamide Nutrition 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- 229960003512 nicotinic acid Drugs 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 229940105150 5-methyltetrahydrofolic acid Drugs 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 101710153422 Procalin Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930003537 Vitamin B3 Natural products 0.000 description 2
- 229930003761 Vitamin B9 Natural products 0.000 description 2
- 239000012496 blank sample Substances 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 235000019160 vitamin B3 Nutrition 0.000 description 2
- 239000011708 vitamin B3 Substances 0.000 description 2
- 235000021470 vitamin B5 (pantothenic acid) Nutrition 0.000 description 2
- 235000019159 vitamin B9 Nutrition 0.000 description 2
- 239000011727 vitamin B9 Substances 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 238000013048 microbiological method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000006552 photochemical reaction Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
- G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
- G01N30/724—Nebulising, aerosol formation or ionisation
- G01N30/7266—Nebulising, aerosol formation or ionisation by electric field, e.g. electrospray
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N2030/042—Standards
- G01N2030/045—Standards internal
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Dispersion Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention provides application of organic salt in a water-soluble vitamin detection kit, and relates to the technical field of detection reagents. The reagent or the kit for detecting the water-soluble vitamins comprises: (a) a water-soluble vitamin; and, (b) an aqueous solution containing an organic salt selected from formate and/or acetate; the concentration of the organic salt is 0.5-10 mM; the water-soluble vitamins comprise at least one of vitamin B1, vitamin B2, nicotinamide, vitamin B5, pyridoxine acid, 5-methyltetrahydrofolate and methylmalonic acid, and organic salts are used as buffer components of the water-soluble vitamins, so that the stability of the water-soluble vitamins in the kit or in each stage in the preparation process of the kit is improved.
Description
Technical Field
The invention relates to the technical field of detection reagents, in particular to application of organic salt in a water-soluble vitamin detection kit.
Background
Vitamins are a class of compounds that cannot be synthesized or are not synthesized in sufficient amounts by the human body and must be taken up directly or indirectly from food. According to their solubility differences, water-soluble vitamins and fat-soluble vitamins can be classified. The water-soluble vitamins are generally more polar and are a class of vitamins that are readily soluble in water, including B vitamins and ascorbic acid, among others. The traditional analysis methods are mainly a microbiological method and a spectrophotometry method, which are time-consuming and labor-consuming, and are difficult to meet the current analysis requirements and development trends. The detection of water-soluble vitamins mainly comprises quantitative analysis of thiamine (VB 1), riboflavin (VB 2), nicotinamide, nicotinic acid, pantothenic acid (VB 5), 4-pyridoxine (VB 6), pyridoxine, 5-methyltetrahydrofolic acid (5-MTHF), methylmalonic acid and the like. The water-soluble vitamins have large polarity, weak retention, poor stability and nonspecific adsorption, which are the difficulties in analyzing the water-soluble vitamins. Vitamins are a class of low molecular weight organic compounds whose stability is affected by a number of factors, such as temperature, redox, light, heat, ph, moisture and trace elements, which are reacted by different reaction pathways: free radical reactions, electron transfer reactions, photochemical reactions, etc. destroy functional structures in vitamin molecules.
The kit containing water-soluble vitamins in the prior art mainly adopts the following solutions to solve the stability problem of the water-soluble vitamins:
(1) The sample is stored by using an ultra-low temperature refrigerator, a large amount of dry ice is required for transporting the sample, and the economic cost is increased.
(2) An antioxidant is adopted to solve a part of stability problems, but the stability of the water dimension index is not obvious by using the antioxidant or a plurality of antioxidants, the combination of the water dimension detection indexes is different, and the effect difference is quite large; the introduction of the antioxidant has an influence on the solubility of a part of the index; the stability of the antioxidant has a larger influence on the peak shape and retention time of part of indexes; antioxidants have an effect on ESI-noise, with elevated baseline, resulting in reduced sensitivity.
(3) The freeze-drying process or the melt-sealing process is adopted to solve the stability problem, the process is complicated, and the economic cost of storage is increased. The freeze-drying process is that the like products at present adopt more processes, the reagent box products are re-dissolved after being added with water after being thawed before being treated, and the pretreatment is carried out subsequently, so that the pretreatment steps are increased.
Therefore, how to simplify the means for improving the stability of the water-soluble vitamins, reduce the cost of the kit, and not influence the detection result of the water-soluble vitamins is a problem to be solved at present.
In view of this, the present invention has been made.
Disclosure of Invention
The invention aims to provide the application of organic salt in preparing a reagent or a kit for detecting water-soluble vitamins, or detecting water-soluble vitamins for non-diagnostic and therapeutic purposes, so as to improve the stability of the water-soluble vitamins in the kit or at various stages in the preparation process of the kit. It is another object of the present invention to provide a reagent or kit for detecting water-soluble vitamins.
In order to solve the technical problems, the invention adopts the following technical scheme:
according to one aspect of the present invention there is provided a reagent or kit for detecting water-soluble vitamins comprising: (a) a water-soluble vitamin; and, (b) an aqueous solution containing an organic salt selected from formate and/or acetate; the concentration of the organic salt is 0.5-10 mM;
the water-soluble vitamins include at least one of vitamin B1, vitamin B2, nicotinamide, vitamin B5, pyridoxine acid, 5 methyltetrahydrofolate, and methylmalonic acid.
Preferably, the formate and acetate concentrations are each independently 1 to 5mM, preferably 5mM.
Preferably, the formate is selected from ammonium formate; and/or the acetate salt is selected from ammonium acetate.
Preferably, the reagent or kit further comprises serum proteins, preservatives and optionally buffer components.
Preferably, the reagent or kit contains (a) a water-soluble vitamin; and, (b) 1-5M ammonium formate, 1-5% wt. serum protein and 0.3-0.5%wt Proclin300, the solvent being water.
According to another aspect of the present invention there is also provided the use of an organic salt in the manufacture of a reagent or kit for the detection of water-soluble vitamins, or for the detection of water-soluble vitamins for non-diagnostic and therapeutic purposes; the organic salt is selected from formate and/or acetate; the concentration of the organic salt is 0.5-10 mM;
the water-soluble vitamins include at least one of vitamin B1, vitamin B2, nicotinamide, vitamin B5, pyridoxine acid, 5 methyltetrahydrofolate, and methylmalonic acid.
Preferably, the formate and acetate concentrations are each independently 1 to 5mM, preferably 5mM;
preferably, the formate is selected from ammonium formate; and/or the acetate salt is selected from ammonium acetate.
Preferably, the detecting comprises analyzing the analyte using liquid chromatography;
preferably, the detecting comprises analyzing the analyte using chromatography tandem mass spectrometry;
preferably, the sample to be tested is a blood sample, a plasma sample or a serum sample.
Preferably, the organic salt is used for preparing a calibrator and/or a quality control material.
Preferably, the preparation of the calibrator and/or quality control comprises the steps of:
dissolving each solid water-soluble vitamin into a stock solution by using a buffer solution, and diluting the stock solution into an intermediate solution; then mixing the formula amount of each intermediate liquid into mixed intermediate liquid; then using buffer solution to dilute the mixed intermediate solution step by step into a calibrator and/or quality control product with a series of concentration gradients; mixing the serial concentration gradient calibrator and/or quality control product with serum matrix to obtain serum matrix calibrator and/or serum matrix quality control product; the buffer solution is an aqueous solution containing the organic salt;
preferably, the serum matrix contains 1 to 5% wt BSA;
preferably, the volume ratio of the calibrator and/or quality control material to the serum matrix at each concentration is independently 1: (19-199), preferably 1:49;
preferably, the aqueous solution of the organic salt is ready for use, and is used no more than 4 hours after preparation.
Compared with the prior art, the invention has the following beneficial effects:
the application of the organic salt in preparing the reagent or the kit for detecting the water-soluble vitamins or detecting the water-soluble vitamins for non-diagnosis and treatment purposes provided by the invention adopts the organic salt as a buffer solution system, so that the stability of process preparation can be improved, the stability of a kit product can be improved, the stability of an analyte in a serum/plasma sample can be improved, and the reproducibility of a test effect can be improved. Specific: formate and/or acetate are used as buffer solution systems, and from the preparation of stock solution to intermediate solution, then to the mixing of intermediate solution, finally, the serum calibrator and quality control product are prepared, so that the problems of storage stability, repeated freeze thawing stability, stability in pretreatment process and stability after sample pretreatment can be effectively solved, the problems of peak shape deterioration, retention time drift and the like caused by the increase of water dimension index can be effectively solved, and the difficulty of storage process can be reduced.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings that are needed in the description of the embodiments or the prior art will be briefly described, and it is obvious that the drawings in the description below are some embodiments of the present invention, and other drawings can be obtained according to the drawings without inventive effort for a person skilled in the art.
FIG. 1 is a flow chart of the preparation of the reagents provided in examples 1 to 4 of the present invention;
FIG. 2 is a chromatogram of the total ion flow of VB2, VB3, VB5, VB6 and VB9 after detection in example 1;
FIG. 3 is a chromatogram of VB1 after detection in example 1;
FIG. 4 is a chromatogram of methylmalonic acid after the test of example 1;
FIG. 5 is a total ion flow chromatogram of VB2, VB3, VB5, VB6 and VB9 after detection in example 2;
FIG. 6 is a chromatogram of VB1 after detection in example 2;
FIG. 7 is a chromatogram of methylmalonic acid after the test of example 2;
FIG. 8 is a chromatogram of the total ion flow of VB2, VB3, VB5, VB6 and VB9 after the detection in example 3;
FIG. 9 is a chromatogram of VB1 after detection in example 3;
FIG. 10 is a chromatogram of methylmalonic acid after the test of example 3;
FIG. 11 is a chromatogram of the total ion flow of VB2, VB3, VB5, VB6 and VB9 after detection in example 4;
FIG. 12 is a chromatogram of VB1 after detection in example 4;
FIG. 13 is a chromatogram of methylmalonic acid after detection in example 4.
Detailed Description
The technical solutions of the present invention will be clearly and completely described in connection with the embodiments, and it is apparent that the described embodiments are some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
According to one aspect of the present invention there is provided a reagent or kit for detecting water-soluble vitamins comprising: (a) a water-soluble vitamin; and, (b) an aqueous solution containing an organic salt, wherein the organic salt is selected from formate and/or acetate.
The water-soluble vitamins in the invention comprise water-soluble vitamins and metabolites thereof, and isotopically labeled water-soluble vitamins, and specifically comprise at least one of vitamin B1 (thiamine), vitamin B2 (riboflavin), vitamin B3 (nicotinamide), vitamin B5 (pantothenic acid), pyridoxine acid, vitamin B9 (5 methyltetrahydrofolate) and methylmalonic acid. Each of the above water-soluble vitamins also includes an isotopically labeled analyte.
The reagents or kits provided herein (a) and (b) may be pre-mixed reagents, such as may be formulated as a working concentration calibrator and/or quality control; alternatively, stock and intermediate solutions of various stages and concentrations. The aqueous solution containing the organic salt in the kit provided by the invention can also be an independently packaged reagent, for example, but not limited to a diluent, and can be used for diluting various levels of stock solutions and/or intermediate solutions of calibrators and/or quality control substances in the kit.
The concentration of the organic salt in the reagent provided by the present invention is 0.5 to 10mM, and may be, for example, but not limited to, 0.5mM, 1mM, 1.5mM, 2mM, 2.5mM, 3mM, 3.5mM, 4mM, 4.5mM, 5mM, 5.5mM, 6mM, 6.5mM, 7mM, 7.5mM, 8mM, 8.5mM, 9mM, 9.5mM or 10mM, or a concentration range between any two of the above. In an alternative embodiment, the formate and acetate concentrations are each independently 1 to 5mM, preferably 5mM. In an alternative embodiment, the formate is selected from ammonium formate. In an alternative embodiment, the acetate salt is selected from ammonium acetate.
In alternative embodiments, the reagent or kit further comprises serum proteins. In alternative embodiments, the concentration of serum protein in the reagent or kit is 1 to 5% wt, for example, but not limited to 1, 2, 3, 4 or 5% wt, or a range of values from any two of the foregoing, preferably 5% wt.
In alternative embodiments, the reagent or kit further comprises other buffer components, including but not limited to one or more of phosphate, sodium chloride, and sodium bicarbonate, used to make up the PBS buffer. The concentration of each buffer component can be selected by those skilled in the art based on known, conventional buffers, and the present invention is not limited thereto.
In alternative embodiments, the reagent or kit further comprises a preservative. In alternative embodiments, the preservative is selected from procalin 300, the concentration of procalin 300 being optionally 0.3 to 0.5% wt, preferably 0.4% wt.
In alternative embodiments, the agent or kit contains (a) a water-soluble vitamin; and, (b) 1-5M ammonium formate, 1-5% wt. serum protein and 0.3-0.5%wt Proclin300, the solvent being water.
According to another aspect of the present invention there is also provided the use of an organic salt in the manufacture of a reagent or kit for the detection of water-soluble vitamins or for the detection of water-soluble vitamins for non-diagnostic and therapeutic purposes.
Wherein the water-soluble vitamins include water-soluble vitamins and metabolites thereof, and isotopically labeled water-soluble vitamins, specifically including at least one of vitamin B1 (thiamine), vitamin B2 (riboflavin), vitamin B3 (nicotinamide), vitamin B5 (pantothenic acid), pyridoxine acid, vitamin B9 (5 methyltetrahydrofolate), and methylmalonic acid. Each of the above water-soluble vitamins also includes an isotopically labeled analyte.
The organic salt used in the above is selected from formate and/or acetate, and the concentration of the organic salt is 0.5 to 10mM, and may be, for example, but not limited to, 0.5mM, 1mM, 1.5mM, 2mM, 2.5mM, 3mM, 3.5mM, 4mM, 4.5mM, 5mM, 5.5mM, 6mM, 6.5mM, 7mM, 7.5mM, 8mM, 8.5mM, 9mM, 9.5mM or 10mM, or a concentration range between any two of the above. In an alternative embodiment, the formate and acetate concentrations are each independently 1 to 5mM, preferably 5mM. In an alternative embodiment, the formate is selected from ammonium formate. In an alternative embodiment, the acetate salt is selected from ammonium acetate.
In alternative embodiments, the detecting comprises analyzing the analyte using liquid chromatography. Liquid chromatography includes, but is not limited to, liquid Chromatography (LC), high Performance Liquid Chromatography (HPLC), or ultra high performance liquid chromatography (UPLC). Some optional chromatographic conditions are selected from any one or a combination of several embodiments:
in an alternative embodiment, the chromatographic column is selected from a C18 chromatographic column.
In an alternative embodiment, the mobile phase comprises mobile phase a, which is preferably an aqueous solution containing formic acid, and mobile phase B, which is preferably an acetonitrile solution containing formic acid; in an alternative embodiment, the formic acid concentration in mobile phase A and mobile phase B are each independently preferably 0.1% wt.
In an alternative embodiment, the elution is a gradient elution. The gradient elution procedure is preferably as follows:
| Time | phase A (%) | Phase B (%) |
| 0.01 | 98 | 2 |
| 1.00 | 98 | 2 |
| 3.00 | 80 | 20 |
| 5.2 | 10 | 90 |
| 6 | 10 | 90 |
| 6.01 | 98 | 2 |
| 7.5 | 98 | 2 |
In alternative embodiments, the detecting comprises analyzing the analyte using chromatography tandem mass spectrometry.
In alternative embodiments, mass spectrometry conditions include using electrospray ion source (ESI), positive ions, MRM scan mode; and the capillary tube has high pressure of 5.0KV, the desolvation gas temperature is 450 ℃, the atomization gas flow rate is 1.5L/min, the desolvation gas flow rate is 5.0L/min, the back blowing gas flow rate is 1.5L/min, and the collision gas flow rate is 0.5mL/min.
In alternative embodiments, the sample detected is a blood sample, a plasma sample, or a serum sample.
In alternative embodiments, the organic salt is used to formulate a calibrator and/or quality control. The calibrator and/or quality control include, but are not limited to, stock and intermediate solutions for each stage and concentration, or dilutions for formulating stock and intermediate solutions for each stage and concentration.
In alternative embodiments, preparing the calibrator and/or quality control comprises the steps of:
dissolving each solid water-soluble vitamin into a stock solution by using a buffer solution, and diluting the stock solution into an intermediate solution; then mixing the formula amount of each intermediate liquid into mixed intermediate liquid; then using buffer solution to dilute the mixed intermediate solution step by step into a calibrator and/or quality control product with a series of concentration gradients; mixing the serial concentration gradient calibrator and/or quality control product with serum matrix to obtain serum matrix calibrator and/or serum matrix quality control product; the buffer solution is an aqueous solution containing the organic salt. The operation of adjusting the concentration of the formulated reagent by adding the buffer solution is not excluded in any of the above steps. The concentration of the specific water-soluble vitamin at any step in the above preparation method can be determined by those skilled in the art according to the conventional manner known in the art and the actual need to be detected by those skilled in the art, and the present invention is not limited thereto.
In alternative embodiments, the serum matrix contains 1 to 5% wt BSA, which may be, for example but not limited to, 1, 2, 3, 4 or 5% wt, or a range of values from any two of the foregoing, preferably 5% wt.
In alternative embodiments, the volume ratio of calibrator and/or quality control to serum matrix at each concentration is independently 1: (19-199), for example, but not limited to, 1:19, 1: 29. 1:49, 1: 99. 1:149 or 1:199, or any two points above, preferably 1:49.
In an alternative embodiment, the aqueous solution of the organic salt is ready for use, and is used no more than 4 hours after preparation.
The invention is further illustrated by the following specific examples, however, it should be understood that these examples are for the purpose of illustration only in greater detail and are not to be construed as limiting the invention in any way.
Example 1
The present example provides a serum calibrator and quality control solution, formulated as follows, in which the buffer solution is an aqueous solution of 5mM ammonium formate, the formulation flow being shown in FIG. 1.
(A) Serum matrix preparation: weighing the background plant source human serum albumin and the buffer solution according to the proportion of 5g/100mL, placing the background plant source human serum albumin and the buffer solution into a PP bottle, adding the preservative Proclin300 according to the proportion of 0.4%, mixing the materials reversely, and placing the materials into an ultrasonic cleaner for ultrasonic mixing for 10min.
(B) Solid powders of VB1 (thiamine), VB2 (riboflavin), VB3 (nicotinamide), VB5 (pantothenic acid), VB6 (pyridoxine), VB9 (5 methyltetrahydrofolate) and methylmalonic acid were weighed, buffer solutions were used to prepare respective component water-soluble vitamin stock solutions, and the respective stock solutions were diluted to an intermediate solution.
(C) And calculating the using amount of the buffer solution according to the concentration of the intermediate solution, adding the buffer solution into a centrifuge tube, sequentially adding the appropriate using amounts of VB1, VB2, VB3, VB5, VB6, VB9 and methylmalonic acid intermediate solution into the buffer solution to prepare mixed intermediate solution, and then gradually diluting by using the buffer solution to obtain the calibrators S1-S7, and the high-value quality control intermediate solution and the low-value quality control intermediate solution.
(D) Taking the calibrator S1-S7 prepared in the step (C) and the high-value quality control product intermediate solution and the low-value quality control product intermediate solution respectively and serum matrixes according to the following steps of 1:49 to obtain serum matrix calibrators J1-J7 and serum matrix quality control substances QCH and QCL, shaking and mixing for 10min, and packaging into brown sample vials at-30deg.C to-15deg.C.
TABLE 1
Example 2
This example provides a serum calibrator and quality control solution that differs from example 1 only in the buffer solution: the buffer solution in this example was 1mM ammonium formate in PBS.
Example 3
This example provides a serum calibrator and quality control solution that differs from example 1 only in the buffer solution: the buffer solution in this example was 5mM ammonium formate in PBS.
Example 4
This example provides a serum calibrator and quality control solution that differs from example 1 only in the buffer solution: the buffer solution in this example was 1mM ammonium formate in PBS.
Example 5
The embodiment provides a detection method of water-soluble vitamins, which comprises the following steps:
1. and (3) preparation of a reagent:
(1) Calibrators J1 to J7 and quality controls QCL and QCH were prepared with reference to the examples described above.
(2) Extracting mixed solution for internal standard work: isotopic analytes of VB1, VB2, VB3, VB5, VB6 (pyridoxine), VB9 and methylmalonic acid were formulated as stock solutions, then diluted to an intermediate, then mixed to an intermediate, then diluted to the concentration ranges of compound J3 corresponding to Table 1, the solvents were: 5mM ammonium formate in water.
(3) And (3) a complex solution: pure water
2. Pretreatment of samples:
(1) Taking 200 mu L of calibrator, quality control product QCL and quality control product QCH in a 2.0mL centrifuge tube, and adding 1000 mu L of prepared internal standard working extraction mixed solution; 200 mu L of pure water is put into a corresponding marked centrifuge tube, and 1000 mu L of internal standard work extraction mixed solution is added as a blank sample, and 1 part of the internal standard work extraction mixed solution is added; 200 mu L of ultrapure water is put into a corresponding marked centrifuge tube, and 1000 mu L of internal standard working solution diluent is added to be taken as a double blank sample, and 1 part of internal standard working solution diluent is added; 2500 r.min- 1 After rotating speed vortex mixing for 5min, 13000 r.min -1 Centrifuging at a rotating speed for 5min.
(2) 800. Mu.L of the supernatant was placed in a 2mL 96-well plate and dried with 40 nitrogen.
(3) Adding 100 mu L of complex solution (mixing), and uniformly mixing for 5min at the normal temperature with the rotating speed of 800 r.min < -1 >. Centrifuging at 4000 r.min < -1 > rotational speed for 10min after uniformly mixing.
3. And (3) quality control product assignment and on-machine detection:
(A) Taking a calibrator, a quality control product and a sample to be detected, carrying out subsequent pretreatment, sucking 100 mu L of supernatant, and feeding into a sample feeding machine and detecting.
(B) LC-MS parameters:
the mass spectrometer is a PreMed5200 liquid chromatography tandem mass spectrometry system manufactured by Hangzhou spectral polymer medical science, inc.
(B1) Liquid chromatography conditions:
chromatographic column C18-AQ 3.0X100 mm,3 μm column
Mobile phase a:0.1% formic acid, aqueous solution; ultrasound for 5min for standby;
mobile phase B:0.1% formic acid, acetonitrile solution; ultrasound for 5min for standby;
column temperature: 35;
sample injection amount: 10 μl (100 μl quantitative loop, microliter sample injection mode, sample height of sample sucking needle 2 mm);
gradient elution:
TABLE 2
(B2) Mass spectrometry conditions:
electrospray ion source (ESI), MRM scan mode.
Ion source parameters:
TABLE 3 Table 3
| Parameter name | Numerical value | Parameter name | Numerical value |
| Capillary high pressure | 5.0KV | Desolventizing gas flow rate | 5.0L/min |
| Temperature of desolvation gas | 450℃ | Counter-blowing flow rate | 1.5L/min |
| Atomized air flow rate | 1.5L/min | Collision gas flow rate | 0.5mL/min |
Mass spectrometry MRM parameters:
TABLE 4 Table 4
Effect example
1. Calibrator and quality control stability:
comparing peak stability of the calibrator and quality control prepared with different buffer solutions of examples 1 to 4 after pretreatment, analysis was performed by the method described in example 5, and the results of example 1 are shown in fig. 2 to 4; the results of example 2 are shown in FIGS. 5 to 7; the results of example 3 are shown in FIGS. 8 to 10; the results of example 4 are shown in FIGS. 11 to 13. As can be seen by comparing the above figures, the aqueous solution of ammonium formate can improve the peak shape stability, wherein the 5mM aqueous solution of ammonium formate is most effective.
2. Stock solution stability and freeze-thaw stability: riboflavin (VB 2) and 5 methyltetrahydrofolate stock solutions were prepared with pure water and 5mM ammonium formate aqueous solution, respectively, at a concentration of 0.5mg/mL, and freeze-thawed three times.
Conclusion: VB2 is prepared by pure water, and is separated out in the freeze thawing process; 5 methyl tetrahydrofolate (VB 9) pure water is prepared, the stability of the stock solution is tested by freeze thawing for a plurality of times, the room temperature is 24 hours, and the ratio is reduced by 20 percent. The stock solution stability formulated with 5mM ammonium formate aqueous solution was not degraded as follows.
3. Quality control product freeze thawing stability: the quality control of example 1 was tested for one, two, three, four, five, and recovery rate, respectively, and the results are shown in table 5. As can be seen from the following table, the recovery of the analyte after multiple freeze thawing is not significantly reduced, indicating good stability of the water-soluble vitamins in the reagents formulated with 5mM ammonium formate aqueous solution.
TABLE 5
Finally, it should be noted that: the above embodiments are only for illustrating the technical solution of the present invention, and not for limiting the same; although the invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical scheme described in the foregoing embodiments can be modified or some or all of the technical features thereof can be replaced by equivalents; such modifications and substitutions do not depart from the spirit of the invention.
Claims (10)
1. A reagent or kit for detecting a water-soluble vitamin, comprising: (a) a water-soluble vitamin; and, (b) an aqueous solution containing an organic salt selected from formate and/or acetate; the concentration of the organic salt is 0.5-10 mM;
the water-soluble vitamins include at least one of vitamin B1, vitamin B2, nicotinamide, vitamin B5, pyridoxine acid, 5 methyltetrahydrofolate, and methylmalonic acid.
2. The reagent or kit according to claim 1, wherein the formate and acetate salts are each independently present in a concentration of 1 to 5mM, preferably 5mM.
3. The reagent or kit according to claim 1, wherein formate is selected from ammonium formate; and/or the acetate salt is selected from ammonium acetate.
4. A reagent or kit according to any one of claims 1 to 3, further comprising serum proteins, a preservative and optionally a buffer component.
5. The reagent or kit of claim 4, wherein the reagent or kit contains (a) a water-soluble vitamin; and, (b) 1-5M ammonium formate, 1-5% wt. serum protein and 0.3-0.5%wt Proclin300, the solvent being water.
6. The use of an organic salt for the manufacture of a reagent or kit for the detection of water-soluble vitamins, or for the detection of water-soluble vitamins for non-diagnostic and therapeutic purposes; the organic salt is selected from formate and/or acetate; the concentration of the organic salt is 0.5-10 mM;
the water-soluble vitamins include at least one of vitamin B1, vitamin B2, nicotinamide, vitamin B5, pyridoxine acid, 5 methyltetrahydrofolate, and methylmalonic acid.
7. Use according to claim 6, characterized in that the formate and acetate concentrations are each independently 1-5 mM, preferably 5mM;
preferably, the formate is selected from ammonium formate; and/or the acetate salt is selected from ammonium acetate.
8. The use of claim 6, wherein the detecting comprises analyzing the analyte using liquid chromatography;
preferably, the detecting comprises analyzing the analyte using chromatography tandem mass spectrometry;
preferably, the sample to be tested is a blood sample, a plasma sample or a serum sample.
9. The use according to any one of claims 6 to 8, wherein the organic salt is used for preparing a calibrator and/or a quality control.
10. The use according to claim 9, wherein preparing the calibrator and/or quality control comprises the steps of:
dissolving each solid water-soluble vitamin into a stock solution by using a buffer solution, and diluting the stock solution into an intermediate solution; then mixing the formula amount of each intermediate liquid into mixed intermediate liquid; then using buffer solution to dilute the mixed intermediate solution step by step into a calibrator and/or quality control product with a series of concentration gradients; mixing the serial concentration gradient calibrator and/or quality control product with serum matrix to obtain serum matrix calibrator and/or serum matrix quality control product; the buffer solution is an aqueous solution containing the organic salt;
preferably, the serum matrix contains 1 to 5% wt BSA;
preferably, the volume ratio of the calibrator and/or quality control material to the serum matrix at each concentration is independently 1: (19-199), preferably 1:49;
preferably, the aqueous solution of the organic salt is ready for use, and is used no more than 4 hours after preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311268846.9A CN117310035A (en) | 2023-09-27 | 2023-09-27 | Application of organic salt in water-soluble vitamin detection kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311268846.9A CN117310035A (en) | 2023-09-27 | 2023-09-27 | Application of organic salt in water-soluble vitamin detection kit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117310035A true CN117310035A (en) | 2023-12-29 |
Family
ID=89296703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311268846.9A Pending CN117310035A (en) | 2023-09-27 | 2023-09-27 | Application of organic salt in water-soluble vitamin detection kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117310035A (en) |
-
2023
- 2023-09-27 CN CN202311268846.9A patent/CN117310035A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110542735A (en) | method for high-throughput determination of multiple fat-soluble vitamins by ultra-high performance liquid mass spectrometry | |
| CN113533555B (en) | Detection kit for detecting immunosuppressant in whole blood by high performance liquid chromatography tandem mass spectrometry and detection method thereof | |
| CN112505179B (en) | Method for measuring isotope dilution ultra-performance liquid chromatography-mass spectrometry combination | |
| CN111830146B (en) | LC-MS/MS high-throughput detection method and kit for 25-hydroxyvitamin D in dried blood slices | |
| CN114935619A (en) | Method and kit for detecting water-soluble vitamins | |
| CN114778747B (en) | Method for simultaneously detecting 16 drugs and metabolites thereof in blood by UPLC-MS/MS method | |
| CN113075305A (en) | Method for quantitatively detecting content of lipid-soluble vitamins in peripheral blood sample | |
| CN114994218B (en) | Detection kit for detecting 4 fat-soluble vitamins in dry blood spots by liquid chromatography-tandem mass spectrometry and detection method thereof | |
| CN113125601A (en) | Method for simultaneously detecting concentrations of 4 fat-soluble vitamins in serum | |
| CN115980248A (en) | Reagent set for detecting methotrexate, folic acid, 5-formyltetrahydrofolic acid and 5-methyltetrahydrofolic acid | |
| CN113917049A (en) | Biological analysis method for clinical research of chlorpromazine and metabolite concentration in plasma sample | |
| CN113189210B (en) | HPLC-MS/MS method for measuring concentration of amygdalin, naringenin and quercetin in blood plasma | |
| CN116087373B (en) | Detection method and pretreatment method for folic acid and 5-methyltetrahydrofolate in erythrocytes | |
| CN116718710A (en) | Kit and method for detecting folic acid and metabolite thereof | |
| CN117310035A (en) | Application of organic salt in water-soluble vitamin detection kit | |
| CN114755323A (en) | Method and kit for detecting content of fat-soluble vitamins in dried blood paper | |
| CN114280178A (en) | Method for detecting multiple water-soluble vitamins | |
| CN113917060A (en) | Quantitative analysis method for paclitaxel in human plasma | |
| CN114137139A (en) | Method and kit for simultaneously detecting 11 vitamins | |
| CN118050442B (en) | Method for determining tacrolimus concentration in whole blood | |
| CN115436502B (en) | Method for detecting concentration of folic acid and derivative thereof in blood plasma based on LC-MS/MS technology | |
| CN112285231B (en) | Method for rapidly detecting glacial acetic acid in rice vinegar | |
| CN115541778B (en) | Detection method for measuring apremilast concentration in human plasma | |
| CN108732254A (en) | A kind of method and its application for amino acid detection | |
| CN116930379A (en) | Liquid chromatography-mass spectrometry method for detecting hexosamine biosynthesis pathway metabolite |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |